AI-generated research brief — verify at source
DTX401 AAV Gene Therapy Cuts Cornstarch Dependency by 41% in GSDIa Phase 3 Trial
In a pivotal phase 3 placebo-controlled trial, a single administration of DTX401 gene therapy produced a statistically significant 41% reduction in daily cornstarch intake at 48 weeks, compared with only 10% in the placebo group (least squares mean reduction; p < 0.0001) in patients with glycogen storage disease type Ia. The magnitude of this reduction closely matched the 45% mean reduction that patients themselves identified as clinically meaningful at baseline, indicating that the effect is not only statistically robust but also relevant to patient-reported treatment goals.
What Was Studied
The trial examined whether a single intravenous infusion of DTX401—an AAV8 viral vector engineered to deliver a functional copy of the human G6PC gene—could meaningfully reduce dependence on dietary cornstarch in patients with GSDIa, a rare inherited disorder in which glucose-6-phosphatase deficiency prevents normal glucose release and forces patients to rely on frequent cornstarch consumption to avoid hypoglycemia. The primary outcome was the percent change from baseline to Week 48 in daily cornstarch intake relative to placebo.
How It Was Studied
DTX401-CL301 was a pivotal, phase 3, double-blind, randomized, placebo-controlled trial enrolling 46 patients aged 8 years or older with confirmed GSDIa. Participants were randomly assigned in a 1:1 ratio, with 21 receiving DTX401 and 25 receiving placebo. The primary efficacy analysis period (PEAP) ran for 48 weeks, after which all participants crossed over in a blinded fashion to the alternate treatment for an additional 48 weeks, allowing assessment of both reproducibility of the effect and longer-term durability out to Week 96. The crossover design was maintained under blinded conditions throughout.
What Was Observed
- DTX401 produced a substantially greater reduction in cornstarch intake than placebo at Week 48. The least squares mean daily cornstarch reduction was 41% (SE 4.6) for DTX401 versus 10% (SE 4.1) for placebo—a statistically significant difference indicating roughly a fourfold greater reduction with active treatment (p < 0.0001).
- The treatment effect was deemed clinically meaningful based on patient-defined targets. Among the 33 participants who provided baseline interviews, the mean desired reduction in cornstarch intake was 45% (median 41%), a threshold that closely tracks the 41% reduction actually achieved with DTX401, suggesting the therapy met real-world patient expectations.
- Benefit appeared to extend and deepen through Week 96. Participants who crossed over to DTX401 after the PEAP achieved greater and faster cornstarch reductions by Week 96 compared with those who received DTX401 in the original PEAP period, and the original DTX401 group also showed further cornstarch reductions at Week 96, suggesting continued or progressive therapeutic effect over time.
- The safety profile was considered acceptable, with manageable hepatic reactions. Transaminase elevations—anticipated responses to AAV-based hepatic gene delivery—were observed but were managed prophylactically with corticosteroids, and no safety signals precluded continued treatment across the trial period.
Why This Matters
GSDIa is a life-threatening metabolic disorder with no approved disease-modifying therapy; current management depends entirely on intensive dietary intervention, including frequent cornstarch ingestion, which is burdensome and imperfect. A gene therapy capable of substantially and durably reducing this dependency represents a fundamentally different therapeutic approach—one that addresses the underlying enzymatic deficiency rather than its metabolic consequences. The alignment between the observed 41% reduction and the patient-identified target of 45% strengthens the argument that this endpoint captures something genuinely important to those living with the disease.
How to Read This Result
While the statistically significant and patient-aligned findings are encouraging, the relatively small sample size (N=46) and a primary efficacy window of 48 weeks limit firm conclusions about long-term durability, immunogenicity, and safety beyond the study period, and results should be interpreted with appropriate caution pending longer follow-up data.
Limitations
The abstract does not explicitly report study limitations.